Home › FDA Decisions › MRK 2026-02-20

MRK FDA Decision Approved · 2026-02-20

Updated September 23, 2026·next FDA decision on the calendar

Price into the decision (T-120)

Daily close, T-120 (9/5/25) through T+5. Run-up high $121.93 on 2/9/26, low $77.6 on 10/2/25 (T-120 to T-1). FDA decision 2/20/26. Historical price action, not a forecast.

Decision facts

FDA decision date2026-02-20

DrugKEYTRUDA + chemo ± bevacizumab (ovarian)

IndicationPlatinum-resistant ovarian cancer

Outcome✓ Approvedprimary-sourced

Decision-day move+0.3%

T-120 run-up (low→high)+43.0% ($82.49→$123.82)

ValidationVerified 2026-08-12: Drugs@FDA, application BLA125514, action date 2026-02-10

Market-cap tierLarge

Cohort decision-day move (history)1.0% median (n=835)

Cohort move is the historical median absolute decision-day move for this market-cap tier across our run-up study. History, not a prediction.

See the full 2026 PDUFA calendar →

Questions

Was KEYTRUDA + chemo ± bevacizumab (ovarian) approved by the FDA?

Yes. The FDA approved the application for KEYTRUDA + chemo ± bevacizumab (ovarian) on February 20, 2026. The primary source is linked on this page.

What was KEYTRUDA + chemo ± bevacizumab (ovarian) under FDA review for?

The application covered Platinum-resistant ovarian cancer. The FDA approved the application on February 20, 2026.

How did MRK stock react to the FDA decision?

On the decision day MRK moved +0.3%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.